Conference Recap Issue: American Society of Hematology and San Antonio Breast Cancer Symposium
ASH 2020: Clinical Updates
The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition featured leading experts in hematology and covered some of the most cutting-edge research in the field.
ASH 2020: COVID-19 and Hematology
Anthony Fauci gave his insight on the coronavirus disease 2019 (COVID-19) for immunocompromised populations at ASH 2020, and leading organizations released fact sheets and recommendations.
ASH 2020: CAR T-Cell Therapy Updates
Exciting new and ongoing developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 62nd American Society of Hematology (ASH) annual meeting.
ASH 2020: The Next Wave
Experts discussed "transformative" treatments and advanced genetic tracing in blood cancer at the 2020 American Society of Hematology Annual Meeting.
2020 SABCS: Topics in Precision Oncology
Biomarkers and genetic testing were topics of interest in precision medicine at the virtual 2020 San Antonio Breast Cancer Symposium.
Lauren M. Corduck, Founder of Oneinforty, Dies at 49; Advocated for Change in BRCA Testing Guidelines
Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.
Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.